On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV Healthcareﾒs cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.

The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssenﾒs 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.